African Swine Fever (ASF) is the greatest threat to the pig industry and ASF virus (ASFV) can result in mortality rates approaching 100%. There are no treatments or internationally licensed vaccines available, and correlates of protection are poorly defined. The moderately virulent Estonia 2014 (Est14) conferred partial protection against homologous virulent Georgia 2007/1 (Geo07) to outbred pigs. Here, we evaluated if Est14 could protect inbred Babraham pigs from Geo07, the causative strain of the ongoing panzootic. Peripheral blood mononuclear cells (PBMCs) from five inbred Babraham and three outbred pigs recovering from Est14 infection were collected at -1, 14- and 27-days post-inoculation (dpi) with Est14. PBMCs were stimulated overnight with Geo07 to assess ASFV-specific responses using spectral flow cytometry. All animals were oronasally challenged with Geo07 28 days after inoculation with Est14. Viremia and clinical scores were monitored throughout the study. T cell activation and degranulation were detected earlier in inbred Babraham pigs at 14 dpi compared to outbred animals at 27 dpi. Cellular responses were more uniform and pronounced in inbred Babrahams than in outbred animals. ASFV-specific responses were detected in polyfunctional CD4-CD8α+β+ cytotoxic T cells and activated CD4+CD8α+β- T-helper cells. After Geo07 challenge, one outbred and one Babraham pig did not recover, but reduced viremia was observed in the remaining animals at 20 days after challenge. This study highlights the utility of inbred Babraham pigs for investigating protective immune responses against ASFV. Further antigen screening with these samples will contribute to the development of more effective ASF vaccines.